En undersøgelse for at lære om, hvordan Safe Bay 3389934 er, dens passende dosis, og hvordan den påvirker deltagerne med sepsis induceret koagulopati
Først i patient, dosisoptrapning, åben etiketundersøgelse for at undersøge sikkerheden, tolerabiliteten, farmakokinetikken og farmakodynamikken af intravenøs infusion af Bay 3389934 til patienter med sepsis induceret koagulopati
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy.
Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels in the body. In severe cases, it can even lead to death.
The main purpose of this first in patient study is to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis induced coagulopathy. For this study, researchers will enroll people receiving treatment for sepsis induced coagulopathy in a hospital intensive care unit (ICU).
For this, the researchers will collect the number of participants with medical problems during and after receiving BAY 3389934. These medical problems are also known as "adverse events". Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.
Participants will be divided into 2 groups. The first group will receive the lowest starting dose of BAY3389934. The researcher will carefully monitor how the participant responds to the medication and may adjust the dose, either increasing or decreasing it based on the safety and the tolerability of the drug. If no serious side effects are reported from the first group, the second group will receive higher dose of BAY3389934.
Each participant will be in the study for around 28 days. During the study, the doctors and their study team will:
- Take blood and urine samples,
- Do physical examinations,
- Check vital signs such as body temperature, blood pressure and heart rate,
- Examine heart health using electrocardiogram (ECG)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Bayer Clinical Trials Contact
- Telefonnummer: 188884229
- E-mail: clinical-trials-contact@bayer.com
Studiesteder
-
-
-
Liège, Belgien, 4000
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Intensive Care
-
-
Antwerp
-
Edegem, Antwerp, Belgien, 2650
- Ikke rekrutterer endnu
- UZ Antwerpen - Intensive Care
-
-
Brussels Capital
-
Woluwe-Saint-Lambert, Brussels Capital, Belgien, 1200
- Ikke rekrutterer endnu
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Intensive Care
-
-
Walloon Brabant
-
Ottignies, Walloon Brabant, Belgien, 1340
- Rekruttering
- Clinique Saint-Pierre d'Ottignies - Intensive Care
-
-
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Ikke rekrutterer endnu
- UC Health University of Colorado Hospital - Medical Intensive Care Unit
-
-
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Frankrig, 37044
- Ikke rekrutterer endnu
- CHRU de Tours - Hôpital Bretonneau - Médecine Intensive Réanimation
-
-
Grand Est
-
Strasbourg, Grand Est, Frankrig, 67091
- Rekruttering
- Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil - Service de Médecine Intensive Réanimation
-
-
New Aquitaine
-
Limoges, New Aquitaine, Frankrig, 87042
- Rekruttering
- Centre Hospitalier Universitaire de Limoges Dupuytren 1 - Service de réanimation polyvalente
-
-
Pays de la Loire Region
-
Angers, Pays de la Loire Region, Frankrig, 49100
- Rekruttering
- Centre Hospitalier Universitaire d'Angers - Médecine Intensive Réanimation et Médecine Hyperbare
-
La Roche-sur-Yon, Pays de la Loire Region, Frankrig, 85000
- Rekruttering
- Centre Hospitalier Départemental Vendée - Service de réanimation polyvalente
-
Nantes, Pays de la Loire Region, Frankrig, 44000
- Rekruttering
- Hopital Hotel Dieu Nantes - Service de Médecine Intensive Réanimation
-
-
Île-de-France Region
-
Garches, Île-de-France Region, Frankrig, 92380
- Ikke rekrutterer endnu
- Hôpital Raymond-Poincaré - Service de Médecine Intensive - Réanimation, Médecine Hyperbare
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Holland, 6525 GA
- Ikke rekrutterer endnu
- Universitair Medisch Centrum St. Radboud - Intensive Care
-
Nijmegen, Gelderland, Holland, 6532 SZ
- Ikke rekrutterer endnu
- Canisius WIlhelmina Ziekenhuis - Intensive Care
-
-
North Brabant
-
's-Hertogenbosch, North Brabant, Holland, 5223 GZ
- Ikke rekrutterer endnu
- Jeroen Bosch Ziekenhuis - Intensive Care
-
-
Overijssel
-
Enschede, Overijssel, Holland, 7512 KZ
- Ikke rekrutterer endnu
- Medisch Spectrum Twente - Intensive Care
-
-
South Holland
-
Rotterdam, South Holland, Holland, 3015 GD
- Ikke rekrutterer endnu
- Erasmus Medisch Centrum - Intensive Care
-
-
-
-
Bavaria
-
München, Bavaria, Tyskland, 81377
- Ikke rekrutterer endnu
- Klinikum der Universität München AöR - Klinik für Anaesthesiologie (Campus Großhadern)
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 51109
- Ikke rekrutterer endnu
- Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik
-
-
Saxony
-
Dresden, Saxony, Tyskland, 01307
- Rekruttering
- Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie
-
Leipzig, Saxony, Tyskland, 04103
- Ikke rekrutterer endnu
- Universitätsklinikum Leipzig AöR_Interdisziplinare Internistische Intensivmedizin
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant must be ≥ 18 and ≤ 85 years of age at the time of signing the informed consent.
- Participants with diagnosed sepsis according to sepsis-3 criteria. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
- participants with suspected or documented origin of infection.
- Participants with coagulopathy defined by at least one of the following within 24 hours prior start of study intervention: INR ≥1.40, platelet count in the range of ≥ 30,000/mm3 to < 150,000/mm3 OR greater than 30% decrease in platelets in 24 hours without other known etiology. The platelet count after decrease should not be < 30,000/mm3.
- Participants must be receiving treatment in an ICU.
- Informed consent of capable participant or, in case of participant being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations.
Exclusion Criteria:
-
Clinically significant active bleeding; known bleeding disorder, history of major traumatic or non-traumatic bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months.
-
Low platelets level or abnormal coagulation status due to any other reason than sepsis.
-
Participants with indication for therapeutic dose of: anticoagulation (heparin, argatroban, vitamin K antagonists/warfarin, dabigatran, apixaban, rivaroxaban, edoxaban), oral antiplatelet agents (clopidogrel, ticagrelor, ticlopidine, prasugrel) except low dose (≤100mg) acetyl salicylic acid (ASA), digoxin, metformin
-
Participants with:
- Uncontrolled malignancy requiring ongoing chemotherapy, radiation therapy, or immunotherapy within the past 6 months with the exception of: low-risk localized prostate cancer (Gleason score is equal to or less than 6 AND Prostate- Specific Antigen is below 10 ng/mL); or cervical carcinoma in situ; or ductal carcinoma in situ; or adequately treated non-metastatic squamous cell skin carcinoma; or adequately treated basal cell skin carcinoma. Patients with breast or prostate cancer receiving single endocrine (hormonal) therapy are eligible if all other cancer-directed treatments were completed more than 6 months prior to screening
- Any hematological malignancy
- Any active or prior malignancy involving the central nervous system (brain or spinal cord), including primary tumors or metastases.
-
Pregnancy or breastfeeding.
-
Chronic liver disease Child-Pugh Class C.
-
Participants experienced major surgery or major trauma (intrathoracic, intra-abdominal, pelvic or femur) or surgery/trauma in any other area with potentially clinically significant consequences due to bleeding within 28 days before study drug administration.
-
Participants experienced neurotrauma or neurosurgery (brain, spine) or orthopedic surgery in spine within 6 months before study drug administration
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1 of BAY3389934
Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours. |
Solution for IV infusion |
|
Eksperimentel: Cohort 2 of BAY3389934
Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours. |
Solution for IV infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antallet af deltagere med TEAE'er (behandling af bivirkninger af behandling)
Tidsramme: Efter den første administration af undersøgelsesintervention til 1 time efter stop fra studieintervention, op til 97 timer
|
Efter den første administration af undersøgelsesintervention til 1 time efter stop fra studieintervention, op til 97 timer
|
|
Alvorlighed af tees
Tidsramme: Efter den første administration af undersøgelsesintervention til 1 time efter stop fra studieintervention, op til 97 timer
|
Efter den første administration af undersøgelsesintervention til 1 time efter stop fra studieintervention, op til 97 timer
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Aktiveret delvis thromboplastin -tid (APTT)
Tidsramme: Fra den første administration af studieintervention dag 1 til dag 6
|
Fra den første administration af studieintervention dag 1 til dag 6
|
|
Prothrombin Time (PT)
Tidsramme: Fra den første administration af studieintervention dag 1 til dag 6
|
Fra den første administration af studieintervention dag 1 til dag 6
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Infektioner
- Systemisk inflammatorisk responssyndrom
- Betændelse
- Hæmatologiske sygdomme
- Blodkoagulationsforstyrrelser
- Hæmoragiske lidelser
- Trombofili
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Sepsis
- Hæmostatiske lidelser
- Dissemineret intravaskulær koagulation
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 22265
- 2024-515635-30-00 (Registry Identifier: CTIS (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .